Reflecting a growing acceptance of obesity as a legitimate medical condition, at least in the United State, a 2024 employer health benefits survey found that 61% of respondents support expanding Medicare (federal health insurance program primarily for individuals aged 65 and older) coverage beyond treatment for T2DM to include GLP-1 therapies for weight management in overweight individuals (Kaiser Family, F, 2024)
At PCOS Sisters, GLP-1 therapy is managed through a hormone-first approach that considers: insulin resistance androgen excess metabolic health long-term weight maintenance nutrient depletion risks individualized dosing When GLP-1 medications are managed by providers who specialize in PCOS, treatment can be optimized to: reduce side effects maximize metabolic improvement support sustainable results Our Approach to GLP-1 Management Unlike many healthcare companies that offer standard dosing protocols, PCOS Sisters focuses on individualized GLP-1 strategies designed for PCOS patients
A.JanssenE
Measuring insulin became much easier after 1959 when a new technique called radioimmunoassay was published by Rosalyn Yalow, a biophysicist, and Solomon Berson, a physician, based at the Veterans Administration Hospital in New York
Knowing your personal risk profile allows you to protect your kidneys while benefiting from GLP-1 therapy
If the medical team determines that a GLP-1 or GIP medication poses a risk to your health due to stomach motility concerns, they will communicate that clearly
